Dyne Therapeutics, Inc. (NYSE:DYN) Receives $27.20 Consensus Price Target from Analysts
Shares of Dyne Therapeutics, Inc. (NYSE:DYN – Get Free Report) have been given an average rating of “Buy” by the five brokerages that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year […]
More Stories
Sangoma Technologies (OTCMKTS:SAMOF) Trading Up 2% – Here’s What Happened
Shares of Sangoma Technologies Co. (OTCMKTS:SAMOF – Get Free Report) were up 2% during trading on Monday . The stock...
OverActive Media (OTC:OAMCF) Shares Down 8.1% – What’s Next?
OverActive Media Corp. (OTC:OAMCF – Get Free Report) dropped 8.1% during mid-day trading on Monday . The company traded as...
Bechtle (ETR:BC8) Shares Up 0.7% – Here’s Why
Bechtle AG (ETR:BC8 – Get Free Report) rose 0.7% during mid-day trading on Monday . The company traded as high...
New Found Gold (OTCMKTS:NFGFF) Stock Price Up 1.2% – Should You Buy?
Shares of New Found Gold Corp. (OTCMKTS:NFGFF – Get Free Report) shot up 1.2% during trading on Monday . The...
Code Chain New Continent (NASDAQ:CCNC) Stock Price Up 2.8% – Still a Buy?
Code Chain New Continent Limited (NASDAQ:CCNC – Get Free Report)’s stock price was up 2.8% on Monday . The stock...
Omnicell (NASDAQ:OMCL) Downgraded to “Hold” Rating by StockNews.com
Omnicell (NASDAQ:OMCL – Get Free Report) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold”...